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Abstract 
Polycystic  Ovary  Syndrome  (PCOS)  represents  a  common  endocrinopathy,  with  anovulation  and 
hyperandrogenism as cardinal symptoms. In recent years it has been recognized that insulin resistance is an intrinsec 
feature  of  the  disorder  and  plays  a  central  role  in  pathogenesis.  PCOS  is  associated  with  important  reproductive 
morbidity as shown by high prevalence of anovulatory infertility, spontaneous abortion, gestational diabetes and pre-
eclampsia. The association of insulin resistance with this reproductive pathology has been well documented. Due to 
major implication of insulin resistance in PCOS pathogenesis, insulin reduction strategies were studied as a possible 
treatment for infertility in PCOS patients. Weight loss, even modest was proved to be a simple and efficient method to 
improve reproductive parameters in PCOS patients and should be recommended to all overweight and obese patients 
with infertility. Metformin was showed to induce ovulation, at least in a subset of patients with PCOS, but there are not 
unequivocal proves concerning its efficacy for pregnancies and live-birth rate, mainly because few trials studied this 
aspect. Therefore there are not enough evidences to recommend metformin for infertility treatment in PCOS. Few small 
studies with newer thiazolidindiones suggest their efficacy for ovulation induction, but further extensive studies are 
needed to confirm these results. In conclusion, reduction of insulin resistance was proved to ameliorate ovulation rate in 
PCOS  patients,  but  strong  evidences  to  sustain  the  utility  of  insulin-sensitizing  drugs  as  a  therapeutic  option  for 
infertility are lacking. Future studies are needed to elucidate these aspects and to characterize the particular subtype of 
patients with higher probability to respond to this treatment. 
 
Introduction 
 
PCOS is one of the most frequent endocrinopathies in the reproductive age years, with a 
prevalence  of  5-10%  [1,2].  At  the  same  time,  PCOS  is  the  most  frequent  cause  of 
hyperandrogenism and anovulatory related infertility. Although it was initially described by Stein 
an Leventhal in 1935, as a reproductive disorder characterized by polycystic ovaries, menstrual 
abnormalities, infertility and obesity, the studies of the last thirty years have demonstrated that 
PCOS  is  a  disorder  associated  with  an  increased  risk  of  type  2  diabetes  mellitus,  metabolic 
syndrome and cardiovascular disease. Nowadays it is believed that insulin resistance is the cause for 
this increased risk. Insulin resistance is a common finding in PCOS patients, with an important role 
in its pathogenesis. Considering that insulin resistance and secondary hyperinsulinemia are involved 
in the occurrence of clinical and paraclinical features of PCOS, many authors have studied the 
efficiency of insulin resistance reduction strategies in the PCOS treatment 
 
PCOS Diagnosis 
 
The criteria used for PCOS diagnosis have changed in time. Until 2003, the PCOS diagnosis 
was based on criteria established by the National Institute of Health (NIH) Conference in 1990: 
clinical and/or biochemical hyperandrogenism associated with chronic anovulation. Exclusion of 
other ovarian, adrenal, thyroid and pituitary disorders are necessary for supporting the diagnosis. In 
2003, the International Conference held in Rotterdam includes the polycystic aspect of the ovaries 
on  transvaginal  ultrasound  as  a  diagnostic  criterion  along  with  hyperandrogenism  and  oligo-
anovulation,  recommending  that  PCOS  diagnosis  should  be  established  if  two  out  of  the  three 
criteria were present. Thus, polycystic ovaries are considered a diagnostic criterion, although some Journal of Medicine and Life  Vol. 1, No.4, October-December 2008 
  416 
authors  consider  this  not  to  be  specific  [3]  because  it  can  also  be  found  in  patients  without 
hyperandrogenism and anovulation [3,4]. After the Rotterdam criteria were introduced, two new 
PCOS phenotypes have been described besides the classic one: patients with polycystic ovaries, 
hyperandrogenism and ovulatory cycles (ovulatory phenotype), and patients with polycystic ovaries 
and anovulation, but without hyperandrogenism. Studying these subtypes of patients, it has been 
observed that patients with the ovulatory phenotype have less insulin resistance than the classic 
phenotype  (5),  and  those  without  hyperandrogenism  have  no  insulin  resistance  [6].  In  these 
subtypes the involvement of insulin resistance in the pathogenesis may be less important. This is 
why the use of Rotterdam criteria may produce confusions when patients other then belonging to 
the classic phenotype are introduced in clinical studies referring to insulin resistance or metabolic 
abnormalities.  Taking  in  consideration  these  aspects,  Androgen  Excess  Society  (AES)  defines 
PCOS as a disorder in which androgen excess is defining and recommends to be included in PCOS 
category only patients with hyperandrogenism. The data available till now about the involvement of 
insulin resistance and high risk for metabolic abnormalities derive from studies that have included 
mainly patients with the classic phenotype. 
 
Insulin resistance in PCOS 
 
The association between insulin resistance and hyperandrogenism has been reported for the 
first time in 1921, when Achard and Thiers have described „diabetes des femmes à barbe”  [7]. 
Nowadays, the relationship between the two conditions is well documented, especialy based on 
studies showing that PCOS patients have insulin resistance and compensatory hyperinsulinemia. 
Although insulin resistance is considered an intrinsec feature of the syndrome, independent of body 
weight, obesity, a frequent feature [8] among PCOS patients (60-70%), has a major contribution to 
the aggravation of the insulin resistance. Insulin resistance was also reported in lean PCOS patients, 
but  its  prevalence  was  variable  and  some  studies  even  failed  to  find  it.  Nowadays,  PCOS  is 
considered a disease with a complex and heterogeneous pathogenesis, different mechanisms being 
involved in different ratios in the appearance of the syndrome. Therefore in certain patients, insulin 
resistance may be less involved in the pathogenesis. 
The etiology of insulin resistance in PCOS, although intensely studied, is not completely 
cleared up. The mechanisms most probably involved are defects at the post receptor level. Thus, in 
50% of the patients autophosphorylation of the insulin receptor (IR), which inhibits the intrinsic 
tyrosine-kinase activity of the IR, has been described [9]. Another post receptor anomaly has been 
described in the muscle cells of the PCOS patients. This consists in the decrease of the insulin-
mediated phosphatidylinositol-3-kinase activity associated to IRS1 (insulin receptor substrate 1), 
involved in the glucose tapping and carbohydrate metabolism (10). Regarding the existence of other 
IR anomalies, it is possible that a small number of IR in adipocytes to be involved in the insulin 
resistance of PCOS, the hypothesis being related in several studies. In exchange, the decrease of 
insulin affinity for its receptors is not considered to have major implications in PCOS pathogenesis. 
It  is  well  known  that  the  abdominal  and  visceral  adiposity  is  associated  with  insulin 
resistance. In PCOS patients an android disposition of adipose tissue has been described in the 
obese patients, as well as in the normal weight patients. Moreover, lean PCOS have much more 
adipose tissue than the normal weight controls. These anthropometric characteristics may contribute 
to  the  PCOS  insulin  resistance.  The  particular disposition  of  adipose  tissue  in  PCOS  could  be 
explained by lipolysis anomalies similar to that found in the patients with android obesity and could 
be explained by a decreased density of β2 adrenergic receptors and hormone-sensible lipase activity. 
Reduced fetal growth could be another possible mechanism of PCOS insulin resistance. This 
has been demonstrated to be a risk factor for metabolic and cardiovascular complications in the 
adult life, presumably due to its association with insulin resistance. Furthermore, it has been shown 
that  reduced  fetal  growth  predisposes  to  hyperinsulinemia,  anovulation  and  ovarian 
hyperandrogenism in patients with premature pubarche [11]. These data suggest that postpubertal Journal of Medicine and Life  Vol. 1, No.4, October-December 2008 
  417 
appearance of the typical PCOS manifestations may be antenatal conditioned, with the possible 
contribution of the environmental and genetic factors. 
The  involvement  of  insulin  resistance  and  secondary  hyperinsulinemia  in  the  PCOS 
pathogenesis is complex, implying the existence of many mechanisms. In vivo and in vitro studies 
have proved that insulin directly stimulates ovarian streroidogenesis at the level of theca cells, along 
with  LH.  This  co-gonadotropic  effect  contributes  to  the  PCOS  hyperandrogenism.  Furthermore 
insulin  decreases  the  sex  hormone  binding  globulin  (SHBG)  levels  by  decreasing  the  liver 
synthesis, raising the level of free testosterone. Also, it decreases the IGFBP1 liver synthesis and so 
it increases IGF1 biodisponibility in the ovaries, causing increased production of ovarian androgens 
through its co-gonadotropic effect. In 50% of the PCOS patients, the adrenal androgens have an 
important  contribution  in  the  appearance  of  hyperandrogenism,  the  involvement  of 
hyperinsulinemia in the alteration of the adrenal steroid genesis being demonstrated [12]. Although 
experimental studies suggested the contribution of hyperinsulinemia to the characteristic changes of 
gonadotrop secretion in PCOS, the clinical studies didn’t succeed to offer solid evidence [13]. 
Recently,  it  has  been  demonstrated  that  insulin  action  in  the  ovaries  is  mediated  by 
inositolglycan at the post receptor level, and not by tyrosine-kinase cascade. This is how we explain 
why the insulin resistance, through IR autophosphorylation, in other tissues doesn’t impede the 
insulin effects in the ovaries [14]. 
These mechanisms through which insulin resistance contributes to the appearance of clinical 
and paraclinical changes in PCOS are mostly demonstrated by in vitro studies. In vivo studies have 
tried  to  reproduce  these  mechanisms  by  acute  administration  of  insulin,  but  they  obtained 
contradictory results. Of the clinical studies, the most convincing have been those that proved the 
amelioration of the clinical and paraclinical parameters by decreasing the insulin resistance, thus 
supporting its pathogenic role. 
 
Infertility in PCOS 
 
Infertility is frequently met in PCOS patients, with a prevalence of 74% [15], and in 40% of 
cases it is actually the motive of presentation to the doctor [16]. Infertility is the consequence of 
chronic anovulation, being usually accompanied by menstrual abnormalities: dysfunctional uterine 
bleeding, oligomenhorrea, amenorrhea. The presence of regular menstrual bleeding doesn’t exclude 
anovulation. Twenty one per cent of the patients with hyperandrogenism have regular menstrual 
cycles that are anovulatory [17]. Furthermore PCOS patients that get pregnant spontaneously or 
after  ovulation  induction  treatments  have  more  frequently  pregnancy  associated  pathology.  So, 
these patients have an increased risk of spontaneous abortion. The exact mechanism that would 
explain  this  complication  is  still  a  matter  of  debate,  both  hyperandrogenism  and  obesity  being 
incriminated as major causes. There are studies that show an increased prevalence of gestational 
diabetes (40-46%) [18] and pregnancy induced hypertension (28,5%)  [19] and have proved the 
association between insulin resistance and these pregnancy complications [18].  
The exact mechanism that determines the chronic anovulation in PCOS has been deeply 
studied, but in spite of all the studies conducted till now, we don’t have a complete understanding of 
all  the  components  implicated  in  this  process.  The  hystologic  studies  performed  in  the  PCOS 
patients have shown ovarian follicles arrested in evolution in the antral stage, containing degenerate 
granulosa cells. Based on these initial studies it has been thought that the big number of ovarian 
follicles found in PCOS are atretic. But subsequent studies demonstrated that the PCOS follicles are 
viable and functional, preserving the capacity of steroidogenesis [20]. Furthermore the granulosa 
cells of PCOS patients have an increased sensibility to FSH stimulation, proving once more their 
viability.  Although  some  authors  affirm  that  the  increased  ovarian  androgens  level  induces 
follicular atresia and incapacity of selection of a dominant follicle [21], there are numerous proves 
that  contradict  this  hypothesis.  Studies  made  on  animals  have  shown  that  testosterone 
administration raises the number of normal preantral and antral follicles  [22]; in these follicles 
testosterone increases the mARN of the androgenic receptors in the granulosa cells, determining Journal of Medicine and Life  Vol. 1, No.4, October-December 2008 
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their  own  proliferation  and  inhibition  of  apoptosis  [23].  Furthermore  testosterone  increases  the 
mARN of the FSH receptor in the granulosa cells [24]. All these support the role of androgens in 
increasing the number of small but functional follicles, pointing to hyperandrogenism as the main 
factor to induce the ovarian changes in PCOS. 
The increased sensibility of the granulosa cells to FSH and the big number of viable follicles 
determine constant levels of estradiol and inhibin, with the loss of physiologic variations of the 
estradiol  levels  that  permit  the  FSH  and  LH  peak,  leading  to  anovulation.  Hyperinsulinemia 
indirectly contributes to anovulation, through hyperandrogenism, but may have a direct role, by 
stimulating the production of estradiol the same as FSH. 
 
Strategies of reducing insulin resistance in PCOS 
 
Since there are numerous evidences of the involvement of insulin resistance in the PCOS 
pathogenesis, strategies of insulin resistance reduction have been studied in the treatment of this 
syndrome. The utility of insulin resistance reduction has been initially suggested by the studies that 
followed the effect of loosing weight in obese PCOS patients. Afterward, there were studies about 
the use of insulin sensitizing drugs in PCOS. First such a report was given in 1994, by Velazquez, 
who  observed  the  decrease  of  the  free  androgens  and  an  improvement  of  the  menstrual 
abnormalities in the patients that have received Metformin  [25]. In the majority of studies, the 
favorable  effects  on  the  endocrine  and  reproductive  anomalies  have  been  accompanied  by  the 
reduction of the insulin resistance, supporting its etiologic involvement. 
Weight loss has been studied by many authors, all of them reporting the improvement of 
hyperinsulinemia and hyperandrogenism, simultaneously with the recovery of normal menstrual 
cycles and the appearance of spontaneous pregnancies in 30% of the patients [26]. These fortunate 
effects were observed even with a modest weight loss of 2-5% [27]. Because of the association 
between obesity and increased risk for spontaneous abortion, the weight loss could have a positive 
effect on the outcome of the pregnancy, although this aspect hasn’t been particularly studied in 
PCOS.  In  obese  patients,  weight  loss  is  associated  with  the  improvement  of  the  lipid  and 
cardiovascular parameters, with benefits in the long run. Also considering the good effects upon the 
fertility, weight loss must be recommended to all obese patients with PCOS as an adjoin to any 
chosen therapy. 
Metformin was the first insulin sensitizing drug to be given to the PCOS patients, initially 
with the purpose of obtaining additional arguments regarding the involvement of insulin resistance 
in  the  PCOS  pathogenesis.  Although  the  study  conducted  by  Velasquez  in  1994  proved  the 
efficiency of Metformin in the improvement of the endocrine status at the same time with the 
insulin resistance reduction, the parallel weight loss of the patients could have been a source of 
error. But the subsequent studies have demonstrated that the Metformin effects are independent of 
the weight variations  [28,29]. Administered to the PCOS patients, Metformin may improve the 
menstrual disorders and anovulation in 50% of the studied patients, with increased probability of 
response in the patients with hyperinsulinemia, less severe menstrual disorders and a lower level of 
free testosterone [28]. Thus, it has been speculated upon the fact that Metformin is efficient in the 
category of patients in which the insulin resistance has an important role in pathogenesis. Not all the 
studies have succeeded in proving the efficiency of Metformin in PCOS patients regarding the 
decrease of hyperinsulinemia and hyperandrogenism [30,31]. The explanation could be the severe 
obesity of the patients in those studies, being well known that an important weight loss is necessary 
to  decrease  the  insulin  resistance  in  severely  obese  patients.  Because  only  50%  of  the  PCOS 
patients respond to Metformin, the proportion of these patients in the studied group could influence 
the final results. Furthermore, it has been proven that you have to give 2,550mg/day to lower the 
insulin resistance in the obese women, doses like 1,500 mg having no effect [32]. Nevertheless, 
most of the studies have used 1,500 to 1,700 mg/day. Journal of Medicine and Life  Vol. 1, No.4, October-December 2008 
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Now, there are studies that prove that Metformin has positive results in the normoponderal 
patients with PCOS, showing a higher efficiency when comparing to the supraponderal and obese 
patients (33). 
Clomiphene citrate is the classic therapy used in the induction of ovulation, being successful 
in 75% of the cases. The rest of 25% are considered resistant to Clomiphene and are usually more 
obese with a higher insulin resistance. The administration of Metformin before Clomiphene, in the 
PCOS patients, has shown a significant increase of ovulation and pregnancy rates when compared 
to placebo [34,35]. There is a well known association between insulin resistance and the risk of 
ovarian  hyperstimulation  syndrome;  when  Metformin  is  administered  in  association  with  the 
gonadotrops,  a  smaller  number  of  follicles,  lower  levels  of  estradiol  and  higher  number  of 
fertilizations and pregnancies are observed [36]. 
In  the  PCOS  patients  that  become  pregnant  there  is  a  high  risk  of  complications,  like 
spontaneous abortion and gestational diabetes. Administered in pregnancy, it has been proved that 
Metformin lowers the risk of these complications. The effect may be due to the decrease in insulin 
resistance  and  hyperandrogenism,  but  also  to  other  mechanisms:  the  normalization  of  the  PAI 
activity and the modulation of the immune response of the endometrium (reflected by the high 
levels of glycodelin induced by Metformin) [37]. The safety of giving Metformin during pregnancy 
hasn’t been proved, being categorized as B drug. Thus, the benefits of Metformin in pregnancy 
must be confirmed by extensive studies, after its safety has been proved. 
Because most of the Metformin studies are small and have no control group, metaanalyses 
of the randomized controlled trials have been made. A recent metaanalysis (April 2008) that took in 
consideration 17 studies with a total of 1,639 patients confirmed the efficiency of Metformin in the 
ovulation induction, compared with placebo, especially in women without resistance to Clomiphene 
(38). At the same time, the association of Metformin and Clomiphene is superior to Clomiphene 
alone  in  ovulation  induction  and  obtaining  the  pregnancy,  especially  in  the  obese  women  or 
resistant to Clomiphene (38). But to estimate the value of an infertility treatment the most important 
is the final result: the birth of a live neonate. Very few studies had as an objective this parameter. 
Recently two big, randomized studies that followed the efficiency of Metformin in increasing the 
number  of  live  neonates  have  been  published.  The  first  study,  done  on  approximately  100 
normoponderal  PCOS  patients,  observed  a  similar  efficiency  of  Metformin  and  Clomiphene  in 
inducing  ovulation,  but  superior  results  in  obtaining  the  pregnancy  for  Metformin  [39].  The 
subsequent pursuit of these patients has shown a bigger number of live neonates in the group treated 
with Metformin. The second study comprised 600 patients (200 patients per each study group) and 
compared the efficiency of Metformin and Clomiphene administered separately and in association. 
Although a superior efficiency in ovulation induction has been observed in the patients that receives 
the combined treatment, this wasn’t followed by a significantly bigger number of live neonates [40]. 
An explanation for the difference between the results of the two studies may be given by the high 
percentage of obese patients in the second study (~70%), being known the high risk of spontaneous 
abortion  caused  by  the  obesity  alone.  In  these  studies,  the  Metformin  administration  has  been 
stopped  the  moment  the  pregnancy  was  obtained,  so  the  possible  effect  of  abortion  reduction 
(reported in previous studies) that could have improved the outcome of the pregnancy could not be 
studied. 
Thiazolidindiones After clinical studies have demonstrated the efficiency of Metformin in 
the amelioration of the endocrine and reproductive parameters, it has been tried to study other 
insulin  sensitizing  drugs  in  the  treatment  of  PCOS.  In  2001,  Azziz  reported  the  results  of  a 
multicentre study on 410 PCOS patients (41) who received Troglitazone in doses of 150, 300 and 
600mg/day  for  44  weeks.  It  has  been  observed  the  improvement  of  the  hyperandrogenism, 
hyperinsulinism, the menstrual abnormalities and anovulation in  a dose-dependent  manner. The 
patients that responded to the treatment were less obese, with less severe menstrual abnormalities, 
hyperinsulinism and hyperandrogenism. In 2000, Troglitazone was withdrawn from use due to the 
severe liver adverse reactions. Thus, the utility of the new thiazolidindiones (Rosiglitazone and 
Pioglitazone)  is  now  evaluated  in  PCOS  patients.  Rosiglitazone  in  4mg/day  dose  [42]  or Journal of Medicine and Life  Vol. 1, No.4, October-December 2008 
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Pioglitazone  30mg/day  dose  [43]  were  proved  to  reduce  the  insulin  resistance  and 
hyperinsulinemia  in  PCOS  patients,  as  well  as  restoring  the  ovulation  and  the  regular 
menstrual cycles. In normoponderal PCOS patients, the clinical and paraclinical amelioration 
was obtained with 2 mg/day of Rosiglitazone, as well as with 4 mg/day, with a greater effect 
of  the  bigger  dose  [44].  Rosiglitazone,  in  doses  of  4mg/day,  determined  clinical  and 
paraclinical improvement in obese patients with increased insulin resistance considered less 
responsive  to  Metformin  [45].  It  was  suggested  that  Rosiglitazone  could  represent  an 
alternative to the treatment of obese patients with high insulin resistance when Metformin is 
not  efficient.  Similar  studies  have  shown  that  Rosiglitazone  (8mg/day),  as  well  as 
Pioglitazone (30mg/day), have superior results in the amelioration of insulin resistance and 
hyperandrogenism,  in  the  supraponderal  and  obese  PCOS  patients,  when  compared  to 
Metformin (2,000-2,550 mg/day) [46, 47]. Furthermore, in patients resistant to Clomiphene, 
the association with Rosiglitazone proved to have better outcome then Metformin association 
in ovulation induction, although there was no significant difference in the pregnancy number 
between the two groups [48]. Unlike Metformin that produces weight loss, thiazolidindiones 
don’t have this favorable effect, but most studies have shown a decrease in the waist/hip ratio 
because  of  the  fat  redistribution  process  induced  by  thiazolidindiones,  with  possible 
modification of the insulin resistance. These arguments of the thiazolidindiones efficacy in 
the treatment of PCOS come from studies made with a small number of patients that is why 
they must be confirmed by bigger randomized studies. Relying on a metaanalysis, it has been 
recently suggested that Rosiglitazone might be associated with an increased risk of coronary 
events,  but  later  studies  didn’t  confirm  this  suspicion.  It  can’t  be  overlooked  that 
thiazolidindiones are placed in the C category regarding pregnancy, because animal studies 
have  shown  a  delay  in  the  fetal  development.  That  is  why  when  you  intend  ovulation 
induction,  this  drug  administration  must  be  made  with  precaution  and  stopped  when 
pregnancy appears. 
 
Conclusions 
 
Insulin resistance involvement in PCOS pathogenesis is clearly supported by in vivo 
and in vitro studies, the most convincing being those that involve insulin resistance reduction 
strategies. The insulin sensitizing drugs have induced in most of the studies, the improvement 
of  the  endocrine  and  reproductive  parameters  simultaneously  with  the  amelioration  of  the 
insulin resistance and hyperinsulinemia, suggesting this to be the main beneficial mechanism 
in PCOS. Data available today support the efficacy of Metformin in ovulation induction, and 
its’ association  with Clomiphene  increases  the  rate  of ovulation and  pregnancies in  PCOS 
patients resistant to Clomiphene. The favorable effects of Metformin are not universal, but 
vary with PCOS subtype, patients with a higher insulin resistance having a better response. At 
the same time, presence of severe obesity may limit the efficacy of Metformin treatment. In 
these situations, the thiazolidindiones could be a therapeutic alternative. Considering all these 
data, there is controversy regarding the final aim represented by the increase in the number of 
live neonates, in part because of the small number of studies. While this effect was described 
in the normal weight patients, in the supraponderal and obese PCOS patients this effect was 
not  reported.  This  fact  may  be  due  to  the  discontinuance  of  Metformin  treatment  at  the 
beginning  of  the  pregnancy  and  with  this  the  possible  effect  of  spontaneous  abortion 
reduction.  Weight  loss  associated  with  Metformin  treatment  might  improve  the  pregnancy 
outcome  and  must  be  recommended  to  all  supraponderal  and  obese  PCOS  patients.  More 
studies are needed to establish exactly the categories of patients that respond to the insulin 
sensitizing  drugs  to  increase  the  efficiency  of  the  therapeutic  strategies.  Also,  it  must  be 
evaluated the safety of Metformin use during pregnancy and the possible implications in the 
increase of the live neonates number. 
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